SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials.
Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation.BMC infectious diseases · 2024Pooled it
- The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis.The Journal of antimicrobial chemotherapy · 2024Pooled it
- Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis.Journal of medical virology · 2023Pooled it
- Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters.EBioMedicine · 2023Pooled it
- Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials.Viruses · 2023Pooled it
- The effect of early COVID-19 treatment with convalescent plasma on antibody responses to SARS-CoV-2.Microbiology spectrum · 2025Trial
- Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial.Frontiers in immunology · 2025Trial
- Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study.Clinical pharmacokinetics · 2024Trial
- Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.JCI insight · 2024Trial
- COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.Expert review of anti-infective therapy · 2026Review
- Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.Cancer cell · 2025Article
- Stable SARS-CoV-2 antibody levels and functionality in serum and COVID-19 convalescent plasma after long-term storage.Vox sanguinis · 2025Article
- Viral and Immune Factors Associated With COVID-19 Outcome in the C3PO Trial of Convalescent Plasma.The Journal of infectious diseases · 2025Article
- A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.The Journal of infectious diseases · 2025Article
- Immunomodulator Stockpiling as a Means of Broad Defense From Biological Threats.Critical care explorations · 2025Article
- Convalescent Plasma and Other Antibody Therapies for Infectious Diseases-Lessons Learned from COVID-19 and Future Prospects.Current topics in microbiology and immunology · 2025Review
- Best practices for clinical trials data harmonization and sharing on NHLBI bioData catalyst (BDC) learned from CONNECTS network COVID-19 studies.Journal of clinical and translational science · 2025Article
- Lessons Learned from National Heart, Lung, and Blood Institute Covid-19 Clinical Trials.NEJM evidence · 2024Article
- Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma.Scientific reports · 2024Article
- Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
26 authors at 17 institutions in 5 countries.
Funding
Abstract
backgroundOutpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results.
methodsWe conducted an individual participant data meta-analysis from outpatient trials to assess the overall risk reduction for all-cause hospitalizations by day 28 in transfused participants. Relevant trials were identified by searching Medline, Embase, medRxiv, World Health Organization COVID-19 Research Database, Cochrane Library, and Web of Science from January 2020 to September 2022.
resultsFive included studies from 4 countries enrolled and transfused 2620 adult patients. Comorbidities were present in 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged from 8 to 14 580 in diverse assays. One hundred sixty of 1315 (12.2%) control patients were hospitalized, versus 111 of 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%-6.0%; P = .001) absolute risk reduction and 30.1% relative risk reduction for all-cause hospitalization. The hospitalization reduction was greatest in those with both early transfusion and high titer with a 7.6% absolute risk reduction (95% CI, 4.0%-11.1%; P = .0001) accompanied by at 51.4% relative risk reduction. No significant reduction in hospitalization was seen with treatment >5 days after symptom onset or in those receiving CCP with antibody titers below the median titer.
conclusionsAmong outpatients with COVID-19, treatment with CCP reduced the rate of all-cause hospitalization and may be most effective when given within 5 days of symptom onset and when antibody titer is higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.